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Safety and efficacy results of switch from imiglucerase to
velaglucerase alfa treatment in patients with
type 1 Gaucher disease
Deborah Elstein,1* Atul Mehta,2,3 Derralynn A. Hughes,2,3 Pilar Giraldo,4,5 Joel Charrow,6 Laurie Smith,7
Suma P. Shankar,8 Thomas N. Hangartner,9 Yune Kunes,10 Nan Wang,11 Eric Crombez,12 and Ari Zimran1
Gaucher disease (GD) is a lysosomal storage disorder; symptomatic patients with type 1 GD need long-term
disease-specific therapy of which the standard of care has been enzyme replacement therapy (ERT). Thirty-
eight of 40 patients (aged 9–71 years) clinically stable on ERT with imiglucerase, safely switched to a
comparable dose of velaglucerase alfa (units/kg) during TKT034, a 12-month, open-label clinical study, and for
10–50 months in an extension study. The most common adverse events (AEs) judged to be drug-related in the
extension were fatigue and bone pain. No drug-related serious AEs were reported. No AEs led to study
withdrawal. At 24 months from baseline (baseline being TKT034 week 0), patients had generally stable
hemoglobin, platelet, spleen, liver, and bone density parameters. Nevertheless, dose adjustment based on the
achievement of therapeutic goals was permitted, and 10 patients, including seven patients who had platelet
counts <100 3 109/L at baseline, were given at least one 15 U/kg-dose increase during the extension. Trends
indicative of improvement in platelet count and spleen volume, and decreasing levels of GD biomarkers,
chitotriosidase and CCL18, were observed. Immunogenicity was seen in one patient positive for anti-
imiglucerase antibodies at baseline. This patient tested positive for anti-velaglucerase alfa antibodies in
TKT034, with low antibody concentrations, and throughout the extension study; however, the patient continued
to receive velaglucerase alfa without clinical deterioration. In conclusion, clinically stable patients can be
switched from imiglucerase to velaglucerase alfa ERTand maintain or achieve good therapeutic outcomes.
Am. J. Hematol. 90:592–597, 2015. VC 2015 The Authors. American Journal of Hematology published by Wiley Periodicals, Inc.
 Introduction
Gaucher disease (GD), an inherited storage disorder of lysosomal glucocerebrosidase deficiency, caused by mutations in GBA, results in intracel-
lular accumulation of glycosphingolipids. The vast majority of cases are classified as type 1 GD, which can present in either childhood or adult-
hood with hepatosplenomegaly, anemia, thrombocytopenia, and bone disease and is distinguished from other types by an absence of central
neurological symptoms [1,2].
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Enzyme replacement therapy (ERT) is the approved first-line treat-
ment approach for symptomatic type 1 GD. Imiglucerase
(CerezymeV
R
, Genzyme, Cambridge, MA) and velaglucerase alfa
(VPRIVV
R
, Shire, Lexington, MA) are both replacement enzymes.
Velaglucerase alfa is produced using gene activation technology in a
human cell line; it has the same amino acid sequence as the naturally
occurring human enzyme [3]. Imiglucerase is produced using
recombinant DNA technology in Chinese hamster ovary cells, and
the amino acid sequence differs from the human enzyme by a single
amino acid substitution [4]. Velaglucerase alfa and imiglucerase have
different glycosylation patterns; velaglucerase alfa contains longer
chain high-mannose type glycans compared with the core mannose
structures in imiglucerase [5]. Taliglucerase alfa ERT is also used to
treat GD, but it was not commercially available at the time velaglu-
cerase alfa was undergoing clinical trials as an investigational drug.
We previously reported that 40 patients were switched from ERT
with imiglucerase to velaglucerase alfa in a phase II/III clinical trial,
TKT034, wherein safety was the primary endpoint [6]. In that trial, one
patient discontinued due to an anaphylactoid reaction during the first
infusion of velaglucerase alfa that was classified as a serious adverse
event (SAE) and considered to be related to the study drug. No other
patient discontinued participation due to an adverse event (AE) or
experienced a drug-related SAE. The four secondary-endpoint varia-
bles, hemoglobin concentration, platelet count, spleen volume, and liver
volume, were stable over the 12-month trial. No patients developed
anti-velaglucerase alfa antibodies, but two of three patients who tested
positive for the presence of anti-imiglucerase antibodies at baseline
(prior to velaglucerase alfa dosing), tested positive for the presence of
very low titers of anti-velaglucerase alfa antibodies at baseline [6].
Patients who completed TKT034 were enrolled in an extension
study, HGT-GCB-044. The primary objective of the extension study
was to evaluate the long-term safety of every-other-week intravenous
infusions of velaglucerase alfa in patients with type 1 GD. This is the
first report of longer term switch-over to velaglucerase alfa in the
context of a clinical trial.
 Patients and Methods
Extension study overview. HGT-GCB-044 was an open-label extension of three
clinical trials of velaglucerase alfa in patients with type 1 GD. Two of the three tri-
als enrolled treatment-na€ıve patients, the results of which are reported elsewhere
[7,8]. We report the extension study results of the cohort who completed the trial
TKT034 [6], which was conducted in patients previously treated with imiglucerase.
Fifteen centers participated in TKT034 [6]; 14 of these were involved in the
extension study, and due to a patient relocating, one additional center in South
Korea took part. The extension study was conducted in compliance with the Inter-
national Conference on Harmonisation (ICH) Guideline for Good Clinical Practice
and Title 21 of the United States Code of Federal Regulations, part 56. At each site,
an institutional review board or independent ethics committee approved the
research. Each patient or their legally authorized representative(s) provided written,
informed consent to participate in the study.
The extension study was registered in the ClinicalTrials.gov database (identifier
NCT00635427).
Patients. Enrollment criteria for the clinical trial TKT034 are detailed elsewhere
[6]. Briefly, adults and children with type 1 GD who were clinically stable and
receiving a stable dose of imiglucerase were enrolled.
Patients were enrolled in the extension study after completing TKT034 (through
week 53). Enrollment exclusion criteria for the extension study included treatment
with an investigational device or drug (except velaglucerase alfa) in the 30 days
before study entry, inability to comply with the protocol, being pregnant or lactat-
ing, and any significant comorbidity.
Velaglucerase alfa. Velaglucerase alfa was administered in a continuous intrave-
nous infusion over 60 minutes every other week. Patients were eligible to partici-
pate in the extension study until commercial velaglucerase alfa became available to
them or the study was discontinued.
Patients received the same dose of velaglucerase alfa that they had received in
TKT034, which was dependent on the dose of imiglucerase that they had received
before switching to velaglucerase alfa [6]. Dose adjustment by 15 U/kg was permit-
ted once every 12 months based on the achievement of therapeutic goals [9], pro-
vided that the dose remained within the range 15–60 U/kg.
Safety assessments. Patients were monitored continuously for AEs, which could
be discovered through observation or examination, questioning, complaint, or clini-
cal laboratory tests. The investigators assessed the relationship of each AE to the
study drug and its severity.
At each infusion visit, vital signs were measured and the use of concomitant
medications (i.e., all nonprotocol treatments) was reviewed. Physical examinations
and clinical laboratory tests were carried out approximately every 12 weeks.
Female patients of child-bearing potential had a urine pregnancy test before
each infusion, which if positive, was to be confirmed by a human chorionic gonad-
otropin blood test and brought to the attention of the Shire medical monitor.
Blood samples were tested for anti-velaglucerase alfa antibodies approximately
every 12 weeks (Supporting Information). An electrochemiluminescence assay was
used to screen samples for the presence of anti-drug antibodies and an enzymatic
activity neutralizing antibody assay was used to analyze samples that screened posi-
tive (methods described previously) [6,10].
Efficacy measurements. Blood hemoglobin concentration, platelet count, chito-
triosidase activity, and chemokine (C-C motif) ligand 18 (CCL18) level were meas-
ured at a centralized laboratory, for consistency, approximately every 12 weeks.
The volumes of the spleen and liver were measured with yearly abdominal MRI
scans. The scans were analyzed by one independent reviewer who was blinded to
the patients’ identities and the study time points when the scans were obtained.
The volumes were normalized to body weight (% BW) and expressed as multiples
of normal (MN) where 1 MN for the liver and spleen was considered 2.5% BW
and 0.2% BW, respectively.
Bone mineral density (BMD) was assessed in adults only (patients aged at least
18 years at the time of consent in the trial TKT034). The lumbar spine and the
proximal end of one or both femurs were scanned at yearly intervals using dual-
energy X-ray absorptiometry (DXA).
Although different DXA scanners were used among the sites, scanners used in
the study were cross-calibrated using a phantom (BMIL Quality Assurance/Quality
Control phantom [11]; BioMedical Imaging Laboratory, Dayton, OH). Hologic
scanners (Hologic, Bedford, MA) were cross-calibrated separately from GE Lunar
scanners (GE Lunar, Madison, WI). Between-manufacturer calibration was achieved
using published equations from clinical cross-calibration studies [12,13]. Where
available, quality assurance data were collected from individual scanners, and cor-
rection equations were applied for longitudinal drifts if needed.
BMD measurements were converted to Z-scores using sex- and race-specific ref-
erence data and to T-scores using Caucasian female reference data, as suggested by
the International Society for Clinical Densitometry [14]; reference data published
by Hologic were used after standardizing the DXA data from GE Lunar scanners to
the Hologic scale.
The DXA data were analyzed at the BioMedical Imaging Laboratory (Wright
State University, Dayton, OH). A single reviewer blinded to treatment information
executed the analysis of the DXA data under the supervision of the laboratory
director (TNH).
Hemoglobin concentration, platelet count, and organ volumes were evaluated as
secondary objectives and all other efficacy variables were evaluated as tertiary
objectives.
Statistical analysis of efficacy variables. Summary statistics at regular time points
were calculated for each efficacy variable. Mean within-patient changes and mean
within-patient percentage changes from baseline were calculated, together with two-
sided 95% confidence intervals. Baseline was defined as before the first dose in
TKT034.
The changes in hemoglobin concentration, platelet count, spleen volume, and
liver volume compared to baseline were the secondary endpoints of the extension
study.
Changes from baseline in plasma chitotriosidase and CCL18 levels and changes
in BMD within the adult cohort were tertiary endpoints. Chitotriosidase levels of
subjects heterozygous for a 24-base-pair duplication in the chitotriosidase gene
were doubled, because it has been established that the average enzyme activity of
heterozygous patients is half that of patients homozygous for the wild type allele
[15]. Homozygous, chitotriosidase-deficient patients were excluded from the chito-
triosidase analysis [16].
During the course of the extension study, velaglucerase alfa was approved for
use in the US and the EU and following this, a large number of patients transi-
tioned to commercial therapy (after a cumulative 24-month treatment period in the
studies). In addition to the analysis of the efficacy results from baseline to 24
months, a longitudinal data analysis was performed using all available data up to
and including the end of the extension study.
Because the expectation was non-deterioration, the mean change from baseline
to 24 months was expected to be <1 g/dL for hemoglobin concentrations, <20%
for platelet counts, and <15% for the organ volumes (as in the trial TKT034) [6].
Two-sided confidence intervals around the mean changes were used for exploratory
tests of these hypotheses; P-values were not calculated. A similar analysis using
90% confidence intervals was performed for the TKT034 trial [6]. For the change-
from-baseline analysis at 24 months, a simple data imputation approach was used
for intermittent missing values: last observation carried forward except for missing
baseline values, which were substituted with the next available measurement.
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Covariate-adjusted linear mixed models were employed for the longitudinal data
analysis. Adjustments were made for the following covariates: the baseline measure-
ment and age at baseline. Because baseline platelet counts likely correlate with sple-
nectomy status, the estimated platelet count means were also adjusted for
splenectomy status. The estimated means for hemoglobin concentration were also
adjusted for sex.
BMD analyses were repeated after excluding all patients who received concomi-
tant bisphosphonates during the studies.
 Results
Thirty-eight of the 40 patients who received at least one full or par-
tial infusion of velaglucerase alfa in TKT034 [6] were enrolled in the
extension study (Table I). The median values at baseline for hemoglo-
bin concentration, platelet count, and normalized liver volume were
normal; however, several patients had platelet counts <150 3 109/L
and all 34 nonsplenectomized patients with baseline spleen volume
measurements had some degree of splenic enlargement. Five patients
had spleen volumes >8 MN (8 MN is a long-term therapeutic goal
proposed by Pastores et al. for spleen size [9]) and each of these five
patients had a platelet count 74 3 109/L at the start of TKT034.
The baseline platelet counts of the three splenectomized patients
(Table I) were 160 3 109/L, 178 3 109/L, and 399 3 109/L and their
hemoglobin levels were 13.5, 13.1, and 12.9 g/dL.
Most patients continued to receive velaglucerase alfa in the exten-
sion study at the same dose that they had received in TKT034. There
were no dose reductions, but 10 adult patients had their doses
increased at least once in the extension study. These patients had one
or more clinical parameters below the therapeutic goal and the inves-
tigators requested a dose increase. The patients were receiving
between 15 and 35 U/kg before dose adjustment: seven of 10
receiving 20 U/kg and three other patients on 27, 30, and 35 U/kg.
No patient had their dose increased above 60 U/kg.
Low baseline platelet counts seemed to be associated with lower
doses since six of eight patients with a baseline platelet count <120
3 109/L and seven of 14 patients with a platelet count <150 3 109/L
were on an imiglucerase dose <30 U/kg before switching.
The median duration of velaglucerase alfa exposure in the exten-
sion study was 21.25 months (range 10.1–50.1 months). Patients
started to transition to commercial velaglucerase alfa after about 24
months of cumulative exposure (i.e., after the first 12 months of the
extension study), following the drug’s first marketing authorization.
Thirty patients completed the extension study. Six patients were
considered to have discontinued when the sponsor decided to termi-
nate the extension study at the end of 2012; five of these transitioned
to commercial velaglucerase alfa. Two patients withdrew consent cit-
ing either a decision to focus on controlling comorbid diabetes (one
patient) or dissatisfaction because of an expectation of improvement
and the constraints of a clinical trial setting (one patient).
Safety and tolerability in the extension study
Three hundred and seventy-five AEs were reported in 35 patients
(Table II). Only nine AEs in eight patients were considered (possibly
or probably) related to velaglucerase alfa treatment. Fatigue (n5 2)
and bone pain (n5 2) were the only AEs purported to be drug-
related that were experienced by more than one person.
The drug-related AEs of fatigue were also categorized as infusion-
related AEs. An infusion-related AE was defined as an AE that began
within 12 hr of the start of an infusion and was judged to be drug-
related. A total of six infusion-related AEs were reported in five
patients during the extension study.
Infusion-related AEs were less common in the extension study
than in TKT034 [6]. All 38 patients received at least one concomitant
medication; however, only two patients required pre-infusion medica-
tion: one patient received loratadine and one patient received parace-
tamol. No patients discontinued from the extension study due to an
AE.
None of the SAEs that were reported were considered related to
velaglucerase alfa treatment (Supporting Information Table SI) and
no study drug-related hypersensitivity reactions were reported. There
were no trends in the physical examination findings, vital signs, or
the clinical laboratory test results to indicate an increased safety risk
with velaglucerase alfa treatment.
Only one patient tested positive for the presence of anti-
velaglucerase alfa antibodies during the extension study. This patient
had anti-imiglucerase antibodies at baseline, some of which






Aged <18 years, n (%) 9 (24)
Male, n (%) 18 (47)







Spleen status, n (%)
Intact 35 (92)
Splenectomized 3 (8)
Pre-switch imiglucerase exposure, months
Median 65
Range 22–192
Pre-switch imiglucerase infusion dose, n (%)
<15 U/kg 1 (3)a
15–29 U/kg 16 (42)
30–44 U/kg 10 (26)
45–59 U/kg 7 (18)
60 U/kg 4 (11)b
Anti-imiglucerase antibody test, n (%)
Negative 35 (92)
Positive 3 (8)
24-Base-pair duplication in chitotriosidase gene, n (%)
Homozygous wild type 25 (66)
Heterozygous 12 (32)
Homozygous (chitotriosidase deficient) 1 (3)
a Lowest dose was 14 U/kg.
b Highest dose was 62 U/kg.
TABLE II. Summary of AEs in the Extension Study
Patients,
n (%) Events
At least one AE 35 (92) 375
At least one (possibly or probably) drug-related AE 8 (21) 9
At least one infusion-related AE 5 (13) 6
At least one serious AEa 6 (16) 14
Life-threatening or fatal 0 0
Possibly or probably drug-related 0 0
At least one severe AEb 4 (11) 12
Possibly or probably drug-related 0 0
Presentation of AEs that occurred any time from a patient’s first infusion
in the extension study until 30 days after their last infusion.
a Reported as serious based on outcome or action criteria usually associ-
ated with events that pose a threat to life or functioning.
b The severity of an AE was assessed with reference to the National Can-
cer Institute Common Terminology Criteria for AEs (version 3.0).
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apparently cross-reacted with velaglucerase alfa [6]. The titer (appa-
rent concentration in ng/mL) for anti-velaglucerase alfa antibodies
increased slowly during 3 years of dosing. At the end of the extension
study, the titer was 1121 ng/mL, which was much lower than the titer
for anti-imiglucerase antibodies that was measured at baseline
(191,100 ng/mL) [6]. The anti-velaglucerase alfa antibody-positive
samples from this patient were analyzed using an enzymatic activity
neutralization assay and shown to have neutralizing antibody (NAb)
activity; no effect was noted on hemoglobin concentration and plate-
let count and no drug-related AEs were reported for this patient.
Two patients became pregnant while enrolled in the extension
study. One patient’s pregnancy was confirmed just over 3 years into
the extension study and the other was after 1.5 years. They elected to
continue velaglucerase alfa treatment during their pregnancies and
signed pregnancy informed consent forms (approved by an institu-
tional review board or independent ethics committee), although one
patient had a 4-month treatment interruption after the confirmation
of pregnancy. Both patients experienced SAEs and nonserious AEs
during pregnancy, but the events were considered to be unrelated to
velaglucerase alfa treatment. The SAEs were oligohydramnios and
postprocedural hematoma after a cesarean section (one patient) and
two urinary tract infections (one patient). The platelet count of the
patient who had a hematoma was 106 3 109/L around the time of
this event. Both patients delivered full-term healthy babies.
Efficacy evaluation
The mean changes from baseline to 24 months, and the 95% confi-
dence intervals around the means, in hemoglobin concentration, pla-
telet count, and the organ volumes were within the pre-specified,
clinically significant ranges: 21 to 1 g/dL, 220 to 20%, and 215 to
15%, respectively (Supporting Information Table SII).
However, there was some suggestion of improvement in platelet
counts and spleen volumes (Fig. 1). In the individual patient data, we
found that 13 patients had a >20% increase (25–199%) in platelet
count by their last assessment, including seven patients who had a
baseline platelet count <150 3 109/L. Eleven patients had a >15%
(17–60%) reduction in spleen volume, including three patients who
had spleens >8 MN at baseline.
Patients who did not have a dose increase are presented separately
from those who did in by-patient line graphs for platelet count and
spleen volume as well as the plasma biomarkers (Supporting Informa-
tion Figs. S1–S4).
In the small group of patients with platelet counts <150 3 109/L
as well as treatment doses <30 U/kg at baseline (n5 7), the platelet
measurements were generally stable during TKT034; five of them ulti-
mately had their doses increased in the extension study, of whom
four had a >20% improvement in platelets at their last assessment.
One patient had a splenectomy during the extension study, after
his infusion at week 149 (month 36 assessment), due to massive
splenomegaly. He experienced an increase of >700% in platelets
(Supporting Information Fig. S1; probably due to decreased splenic
sequestration of platelets). This patient’s hematological measurements
up to and including month 36 were with an intact spleen and he had
hematological measurements up to month 45 only. Therefore, his
post-splenectomy measurements are not included in Fig. 1 or Sup-
porting Information Table SII.
Figure 1. Hematological and visceral assessments: changes from baseline to annual assessments based on covariate-adjusted linear mixed models. Each
number in brackets indicates the number of patients with available data at that time. Adjustments were made for the following covariates: the baseline mea-
surement and age at baseline. The estimated means for hemoglobin concentration and platelet count were also adjusted for sex and splenectomy status,
respectively.
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Mean decreases over time in levels of chitotriosidase and CCL18
were observed (Fig. 2); the two biomarkers decreased in almost all
patients (Supporting Information Figs. S3 and S4).
Hemoglobin concentration, platelet count, spleen and liver vol-
umes, and chitotriosidase and CCL18 levels in the patient who had a
4-month treatment interruption during pregnancy all deteriorated
during the break (which was in her fifth year of trial participation).
The patient then improved after resuming treatment (Supporting
Information Figs. S1–S4 show platelets, spleen volume, and
biomarkers).
All 29 adult patients had serial DXA scans, most of whom had a
baseline T-score –1 at the lumbar spine (n5 19), the femoral neck
(n5 19), or both, that is, within the normal range. BMD Z-scores
were generally maintained over time, and there was little to no differ-
ence when patients who received bisphosphonates were excluded
from the analysis (Fig. 2). At 51 and 63 months from baseline, there
were only four patients with available data, and the mean change in
lumbar spine Z-score peaked and then fell (Fig. 2).
 Discussion
We previously reported safety and efficacy results in 40 patients
switching from imiglucerase to velaglucerase alfa treatment in the 12-
month clinical trial TKT034 [6]. The extension study for patients
who completed the trial provides longer-term safety and efficacy data
for 24 up to 63 months.
The vast majority of AEs reported in the extension study were
unrelated to velaglucerase alfa treatment. Infusion-related AEs
affected only five patients and only two patients required pre-infusion
medication. No drug-related SAEs were reported and no patient dis-
continued due to an AE.
Only one patient tested positive for the presence of antivelaglucer-
ase alfa antibodies; this patient did not deteriorate clinically.
Two patients became pregnant and continued to receive ERT dur-
ing their pregnancies. Their experience of AEs does not change the
risk-benefit profile of velaglucerase alfa and supports the decision not
to interrupt treatment during pregnancy. In general, evidence regard-
ing the safety of ERT use in pregnancy is limited, but good maternal
and neonatal outcomes were reported based on records of 21 female
patients receiving ERT, which were collected and examined retrospec-
tively from six clinical sites [17], and the two cases in the present
study are consistent with those findings.
The four clinical variables that were stable over 12 months in
TKT034 (hemoglobin concentration, platelet counts, and spleen and
liver volumes) remained stable in a subsequent 12-month period on
velaglucerase alfa treatment, based on mean changes from baseline to
24 months that were within prespecified, clinically significant ranges.
Hemoglobin level, liver volume, and BMD Z-scores (age-standar-
dized BMD) in adults were generally stable over time. However, there
were trends toward improvement in platelet counts and spleen vol-
umes, and the plasma biomarker levels were clearly reduced.
About half of the patients with baseline platelet counts <150 3
109/L and most patients with spleens >8 MN at baseline experienced
what we judged to be a clinical improvement (>20% increase in pla-
telets, >15% reduction in spleen volume). However, not all patients
who experienced clinical improvements had low platelet counts or
particularly large spleens on study entry; specifically, patients with
low platelet counts and larger spleens made up seven of 13 patients
Figure 2. Exploratory efficacy assessments: changes from baseline to annual assessments based on covariate-adjusted linear mixed models. Each number
in brackets indicates the number of patients with available data at that time. Seven adults received bisphosphonates concomitantly at least once during the
studies, and 22 adults (lower right panel) did not receive bisphosphonates. Adjustments were made for the following covariates: the baseline measurement
and age at baseline. BMD: bone mineral density.
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and three of 11 patients in total who experienced improvements in
platelets and spleen volume, respectively.
Ten of 38 patients had their dose increased during the extension
study. This probably contributed to the trends observed in platelet
count and spleen volume, although clinically significant within-
patient changes were also observed outside of the group who had
dose adjustments. Specifically, seven of 13 patients who experienced
an increase in platelets of >20% and five of 11 patients whose
spleen volume decreased by >15% had their dose increased. There-
fore, the results show that switching patients previously treated on
a stable dose of imiglucerase to velaglucerase alfa was generally not
associated with deterioration and for some patients, despite being
apparently stabilized, there was room for clinical improvement,
with dose adjustment for some patients and without it for others.
Further investigation is needed to confirm the results and, if perti-
nent, look for patient- or drug-specific factors that might explain
them.
Considering that low platelet counts seemed to associate with
lower treatment doses or, perhaps more importantly, that most
patients who had a dose adjustment achieved some clinical improve-
ment, one might speculate that some pre-switch imiglucerase doses
were not optimal. However, we cannot judge whether imiglucerase
doses were optimal based on this study. Patients were not on imiglu-
cerase treatment in the study.
Baseline chitotriosidase and CCL18 levels varied widely (108–
30,785 nmol/mL/hr and 49–1582 ng/mL, respectively). The median
values were clearly elevated compared with values reported for
healthy controls or asymptomatic glucocerebrosidase-deficient
patients; since Gaucher cells secrete chitotriosidase and the chemo-
kine CCL18 [18,19], these results may indicate that there may be sig-
nificant glucosylceramide storage even after 2 or more years of
previous imiglucerase treatment, and even though chitotriosidase is
not glucosylceramide storage-specific.
Our analyses were limited by patient number attrition (less than
half of the patients had 3 or more years of velaglucerase alfa exposure
including time in TKT034), which was largely due to patients transi-
tioning to commercial velaglucerase alfa. Linear mixed effects models
that incorporated all available data and included covariate adjust-
ments were used to analyze the longer-term efficacy data and mini-
mize the impact of the missing data (missing mechanism was
considered to be missing at random). We had to assume that there
had been no longitudinal drift in DXA scanners if the quality assur-
ance data were unavailable, which was another limitation; this may
have affected the accuracy of the DXA results.
In conclusion, this study reinforces the safety profile and efficacy
of velaglucerase alfa reported in previous studies [7,8,20] and the low
incidence in the long term of anti-drug antibody production and
hypersensitivity reactions. Clinically stable patients can be safely
switched from imiglucerase to velaglucerase alfa ERT and maintain or
achieve good outcomes.
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